Lucy Donaldson
Jonathan Morris
Steve Harper

Lucy Donaldson is Associate Pro-Vice chancellor for Research academy and Career Development at the University of Nottingham, and Professor of Sensory Physiology. Her expertise in acute and chronic pain, and other sensory neuroscience has resulted in the identification of novel mechanisms that are targets for non-opioid analgesics in arthritis, diabetes and other chronic pain conditions. She is a serial entrepreneur, founder of three companies, and Fellow of the Physiological Society and Royal Society of Biology

Jonathan Morris is Professor of Chemistry and Pro Vice Chancellor of Research Training & Entrepreneurship at the University of New South Wales, Sydney. His research group focuses on developing new medicinal chemistry compounds using his expertise in synthetic organic chemistry. He has particular expertise in development of small molecules that can selectively and potently target splicing factor kinases and has delivered such as compound that has now entered the clinic for treatment of diabetic macular oedema.

Steven Harper is a consultant nephrologist at Southmead Hospital and Honorary Professor in the School of  Physiology, Pharmacology and neuroscience at the University of Bristol. He has a lifetime of experience of treating patients with kidney disease, diabetes and other complex disorders, and a research career that has spanned academia and biotech. His joint discovery of novel splice variants of VEGF led to the licensing of patents from Bristol into multiple biotech companies, and he was a Founder and is a Director of Exonate Ltd

David Bates
Keith McDonald
Andy Chapman
David Bates is Director of the Centre for Cancer Sciences and Professor of Oncology at the University of Nottingham. His research has focused on angiogenesis and vascular permeability, the underlying causes of disease in cancer, diabetes, heart disease, and kidney failure, amongst many other pathologies. His laboratory focusses on the biology of alternative splicing of angiogenic and immune factors, in acute myeloid leukemia, melanoma and bile duct and colorectal cancers. He is a co-founder and Chief Scientific Officer at Exonate Ltd. Keith McDonald is a former senior executive of Lloyd’s Banking Group with many years of corporate finance experience. He acts as a non-executive director and mentor to several companies ranging from recent start-ups in the hospitality sector to an AIM listed software company with market capitalisation of £0.5Bn. He was also instrumental in the $800M sale of Zylo (University of Bristol spin out) to Novo Nordisk in 2018 Andy Chapman has worked in leading academic institutions in the UK and Spain where his varied research activities have led to several high impact articles and books. He has specific experience in funding acquisition and a previous chemical SME in which he led customer driven research and development. He is currently CEO of Carbometrics Limited.

Neil Miller
Richard Rutter
Grant Hawthorne
Neil has spent almost 25 years working in the Pharma & Biotech industry. He trained in the UK and US as an organic chemist before joining GlaxoSmithKline’s R&D organisation where he led small molecule projects from start-of-chemistry through to early clinical studies, predominantly in the neuroscience therapeutic area. More recently he was CSO then CEO of Auspherix Ltd an early-stage biotech developing a novel class of antibiotics. Neil is a co-founder of NRG Therapeutics Ltd. Richard is a molecular pharmacologist with over 20 years drug discovery experience. Following his academic training at the University of Oxford and UCL, he joined Merck (UK) and then GlaxoSmithKline (Singapore) where he oversaw a portfolio of neuroscience projects spanning from early target identification through to development candidate nomination. He was CSO at Auspherix Ltd where he led the development of a novel class of antibiotics and is a co-founder of NRG Therapeutics Ltd. Grant qualified as an accountant in South Africa and is a chartered member of the Securities Institute. Following his arrival in the UK 20 years ago, he has acted as CFO/COO for several private equity backed biotech and tech companies (including Alchemab Therapeutics Ltd, Auspherix Ltd, Inotec AMD, Cronto & Azea Networks), collectively raising over £100m and overseeing a number of successful exits. Grant is a co-founder of NRG Therapeutics Ltd.

Emenda Therapeutics
102 Queen Edith's Way, Cambridge, CB1 8PP
University of Nottingham
Faculty of Medical and Health Sciences
University of New South Wales, Sydney
NSW 2052

Contact: info@emendatherapeutics.com